By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.

Clarient will market and sell the OncoCEE-BR test to community hospitals, pathologists, and medical oncologists. Biocept will run the test in its CLIA laboratory and Clarient Pathology Services will analyze the results.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.